Methods of treating inflammatory bowel disease with amd3100 and tacrolimus

Abstract

The present invention relates to the field of inflammatory bowel disease. In one aspect, the present invention provides methods for treating inflammatory bowel disease in a patient comprising administering to the patient a therapeutically effective amount of a stem cell mobilizer and an immunosuppressive agent. In particular embodiments, the present invention provides a method for treating inflammatory bowel disease in a patient comprising administering to the patient a therapeutically effective amount of an agent that mobilizes CD34+ and/or CD133+ stem cells and a low dose of an immunosuppressive agent.

What is claimed is: 
     
         1 . A dosing regimen comprising:
 administering to a patient with inflammatory bowel disease a therapeutically effective amount of a stem cell mobilizer and an immunosuppressive agent.   
     
     
         2 . The dosing regimen of  claim 1 , wherein the stem cell mobilizer is selected from the group consisting of AMD3100, AMD3465, TG-0054, G-CSF, GM-CSF, SDF-1, and SCF. 
     
     
         3 . The dosing regimen of  claim 1 , wherein the stem cell mobilizer is a CXCR4 antagonist. 
     
     
         4 . The dosing regimen of  claim 1 , wherein the stem cell mobilizer is AMD3100. 
     
     
         5 . The dosing regimen of  claim 1 , wherein the immunosuppressive agent is selected from the group consisting of Tacrolimus, cyclosporine, Orthoclone OKT3, mycophenolate and sirolimus. 
     
     
         6 . The dosing regimen of  claim 1 , wherein the immunosuppressive agent is Tacrolimus. 
     
     
         7 . The dosing regimen of  claim 1 , wherein the immunosuppressive agent is administered in a low dose amount. 
     
     
         8 . The dosing regimen of  claim 1 , wherein the stem cell mobilizer is AMD3100 and the immunosuppressive agent is Tacrolimue. 
     
     
         9 . A dosing regimen comprising:
 administering to a patient with inflammatory bowel disease a therapeutically effective amount of an agent that mobilizes at least one of CD34 +  and CD133 +  stem cells and a low dose of an immunosuppressive agent.   
     
     
         10 . The dosing regimen of  claim 9 , wherein the agent that mobilizes at least one of CD34 +  and CD133 +  stem cells is AMD3100 and the immunosuppressive agent is Tacrolimus.